Monovalent Inactivated Rabies Vaccine (mRABV): Production, Schedule, and Efficacy

Monovalent inactivated rabies vaccine (mRABV) contains a single rabies virus strain (usually PV or Pitman-Moore) grown in cell culture (Vero, human diploid, chick embryo), inactivated with β-propiolactone, purified, and adjuvanted (aluminum phosphate/gel).

Indications

• Post-exposure prophylaxis (PEP): After bite/scratch from potentially rabid animal.
• Pre-exposure prophylaxis (PrEP): High-risk groups (veterinarians, lab workers, travelers to endemic areas).

PEP Schedule (WHO/Essen)

• Day 0, 3, 7, 14 (4-dose) or Day 0, 3, 7, 14, 28 (5-dose).
• Day 0: also administer rabies immunoglobulin (RIG) infiltrated around wound (if category III exposure).

PrEP Schedule

• Days 0, 7, 21 or 28.
• Booster or titer check every 1–3 years if ongoing risk.

Safety and Efficacy

• >99% seroconversion after full series.
• Common: injection site pain, headache, myalgia, fatigue.
• Rare: anaphylaxis, neuroparalytic events (very rare with cell-culture vaccines).
• Safe in pregnancy, children, immunocompromised (though immune response may be blunted).

Global Context

Rabies causes ~59,000 deaths/year (mostly Asia/Africa). mRABV is WHO-prequalified. Timely PEP is 100% effective. Dog vaccination is the ultimate control strategy.